Exhibit 99.2

img193038000_0.jpg

 

Arcadia Biosciences, Inc.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)

 

 

 

As of December 31,

 

 

 

2025

 

 

2024

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

259

 

 

$

4,242

 

Short-term investments

 

 

4,304

 

 

 

 

Accounts receivable and other receivables, net of allowance for credit loss
   of $559 and $0 as of December 31, 2025 and 2024, respectively

 

 

425

 

 

 

1,175

 

Inventories

 

 

1,212

 

 

 

904

 

Note receivable — current, net of allowance for credit losses (Note 8)

 

 

 

 

 

1,894

 

Prepaid expenses and other current assets

 

 

156

 

 

 

931

 

Current assets of discontinued operations — GoodWheat

 

 

 

 

 

96

 

Total current assets

 

 

6,356

 

 

 

9,242

 

Property and equipment, net

 

 

8

 

 

 

41

 

Right of use assets

 

 

 

 

 

137

 

Intangible assets, net

 

 

39

 

 

 

39

 

Note receivable — noncurrent, net of allowance for credit losses (Note 8)

 

 

 

 

 

3,966

 

Other noncurrent assets

 

 

143

 

 

 

92

 

Total assets

 

$

6,546

 

 

$

13,517

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

1,789

 

 

$

2,108

 

Amounts due to related parties

 

 

 

 

 

30

 

Operating lease liability — current

 

 

 

 

 

155

 

Other current liabilities

 

 

270

 

 

 

270

 

Total current liabilities

 

 

2,059

 

 

 

2,563

 

Common stock warrant and option liabilities

 

 

347

 

 

 

2,731

 

Other noncurrent liabilities

 

 

 

 

 

2,000

 

Total liabilities

 

 

2,406

 

 

 

7,294

 

Commitments and contingencies (Note 14)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.001 par value—150,000,000 shares authorized as of
   December 31, 2025 and December 31, 2024; 1,373,120 and 1,364,940 shares
   issued and outstanding as of December 31, 2025 and December 31, 2024,
   respectively.

 

 

65

 

 

 

65

 

Additional paid-in capital

 

 

285,292

 

 

 

285,036

 

Accumulated deficit

 

 

(281,217

)

 

 

(278,878

)

Total stockholders' equity

 

 

4,140

 

 

 

6,223

 

Total liabilities and stockholders’ equity

 

$

6,546

 

 

$

13,517

 

 

 

1


 

Arcadia Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

(In thousands, except share data and per share data)

 

 

 

Year Ended December 31,

 

 

 

2025

 

 

2024

 

Revenues:

 

 

 

 

 

 

Product

 

$

4,858

 

 

$

5,012

 

License

 

 

 

 

 

7

 

Royalty

 

 

 

 

 

26

 

Total revenues

 

 

4,858

 

 

 

5,045

 

Operating expenses (income):

 

 

 

 

 

 

Cost of revenues

 

 

3,098

 

 

 

2,963

 

Research and development

 

 

9

 

 

 

53

 

Gain on sale of intangible assets

 

 

(750

)

 

 

(4,000

)

Impairment of property and equipment

 

 

 

 

 

36

 

Change in fair value of contingent consideration

 

 

(2,000

)

 

 

 

Selling, general and administrative

 

 

7,001

 

 

 

9,641

 

Total operating expenses

 

 

7,358

 

 

 

8,693

 

Loss from operations

 

 

(2,500

)

 

 

(3,648

)

Interest income

 

 

221

 

 

 

782

 

Credit loss

 

 

(4,745

)

 

 

 

Other income, net

 

 

2,309

 

 

 

31

 

Change in fair value of common stock warrant and option liabilities

 

 

2,384

 

 

 

(1,474

)

Net loss from continuing operations before income taxes

 

 

(2,331

)

 

 

(4,309

)

Income tax expense

 

 

(8

)

 

 

(8

)

Net loss from continuing operations

 

 

(2,339

)

 

 

(4,317

)

Net loss from discontinued operations — GoodWheat

 

 

 

 

 

(2,721

)

Net loss attributable to common stockholders

 

$

(2,339

)

 

$

(7,038

)

Net loss per share attributable to common stockholders:

 

 

 

 

 

 

Basic and diluted from continuing operations

 

$

(1.71

)

 

$

(3.17

)

Basic and diluted from discontinued operations

 

$

 

 

$

(2.00

)

Net loss per basic and diluted share attributable to common stockholders

 

$

(1.71

)

 

$

(5.17

)

Weighted-average number of shares used in per share calculations:

 

 

 

 

 

 

Basic and diluted

 

 

1,368,057

 

 

 

1,363,303

 

Other comprehensive income, net of tax

 

 

 

 

 

 

Unrealized gains on available-for-sale securities

 

$

 

 

$

127

 

Reclassification adjustment for gains on available-for-sale securities included in net loss

 

$

 

 

$

(228

)

Change in unrealized gains on available-for-sale securities

 

$

 

 

$

(101

)

Comprehensive loss

 

$

(2,339

)

 

$

(7,139

)

 

2


 

Arcadia Biosciences, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

Year Ended December 31,

 

 

 

2025

 

 

2024

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$

(2,339

)

 

$

(7,038

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

Change in fair value of common stock warrant and option liabilities

 

 

(2,384

)

 

 

1,474

 

Change in fair value of contingent consideration

 

 

(2,000

)

 

 

 

Depreciation

 

 

32

 

 

 

113

 

Lease amortization

 

 

122

 

 

 

652

 

Amortization of note receivable discount

 

 

(69

)

 

 

(157

)

Gain on disposal of property and equipment

 

 

 

 

 

(65

)

Gain on sale of intangible assets

 

 

(750

)

 

 

(4,000

)

Gain on receipt of Above Food Ingredients, Inc. common stock

 

 

(1,067

)

 

 

 

Unrealized gain subsequent to receipt of Above Food Ingredients, Inc. common stock

 

 

(1,237

)

 

 

 

Stock-based compensation

 

 

234

 

 

 

512

 

Credit loss

 

 

4,745

 

 

 

 

Write-down of inventories

 

 

 

 

 

154

 

Impairment of property and equipment

 

 

 

 

 

36

 

Write-down of non-controlling interest

 

 

 

 

 

138

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable and other receivables

 

 

165

 

 

 

(762

)

Inventories

 

 

(308

)

 

 

550

 

Prepaid expenses and other current assets

 

 

775

 

 

 

(124

)

Other noncurrent assets

 

 

(50

)

 

 

72

 

Accounts payable and accrued expenses

 

 

(399

)

 

 

(303

)

Amounts due to related parties

 

 

(30

)

 

 

(29

)

Other current liabilities

 

 

(57

)

 

 

 

Operating lease payments

 

 

(122

)

 

 

(850

)

Net cash used in operating activities

 

 

(4,739

)

 

 

(9,627

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

Proceeds from sale of property and equipment

 

 

 

 

 

334

 

Proceeds from sale of investments

 

 

 

 

 

5,024

 

Proceeds from sale of intangible assets

 

 

750

 

 

 

4,000

 

Cash paid related to sale of GoodWheat

 

 

 

 

 

(2,000

)

Purchases of property and equipment

 

 

 

 

 

(16

)

Net cash provided by investing activities

 

 

750

 

 

 

7,342

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

Proceeds from ESPP purchases

 

 

6

 

 

 

9

 

Net cash provided by financing activities

 

 

6

 

 

 

9

 

Net decrease in cash and cash equivalents

 

 

(3,983

)

 

 

(2,276

)

Cash and cash equivalents — beginning of period

 

 

4,242

 

 

 

6,518

 

Cash and cash equivalents — end of period

 

$

259

 

 

$

4,242

 

 

# # #

3